GENPREX (GNPX)
(Real Time Quote from BATS)
$0.44 USD
-0.04 (-8.31%)
Updated Sep 12, 2024 03:14 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
GNPX 0.44 -0.04(-8.31%)
Will GNPX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GNPX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GNPX
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
GNPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
Other News for GNPX
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa? Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Genprex plans to launch separate company to focus on gene therapy
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Biotech Alert: Searches spiking for these stocks today